Additional studies employing conventional sequencing evaluated the concordance of the specific mutations on other genes participating in the oncogenic process of CMM, like CDKN2A, MITF, EGFR, CCND1, cMET, and cKIT and others, evidencing differences in genes selected during tumor progression (like CDKN2A, MITF, etc.)[11]. This evidence concerns the gene MITF and neoplasm.